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Hepatitis B virus (HBV) has been classified into 8genotypes (A-H) based on an intergroup diver-gence of 8% or more in the complete nucleotide
sequence.1,2 Figure 1 illustrates the geographic distribution
of HBV genotypes, but existing information is incomplete,
as data in many parts of the world are not available or are
based on very small numbers of patients studied. Addition-
ally, the distribution of HBV genotypes may vary with time
and with population migration, as demonstrated in a recent
study in the United States.3 Furthermore, subtypes have now
been identified within some genotypes.
In the 2.5 years since our last editorial,1 there has been
an explosion of knowledge in the literature on the epide-
miology of HBV genotypes, and their association with
hepatitis B e antigen (HBeAg) seroconversion, activity of
liver disease, and treatment response.
HBV Genotypes, HBeAg Seroconversion and
Outcome of Chronic HBV Infection
Most of the information on the clinical significance of
HBV genotypes has been based on studies of patients with
chronic HBV infection in Asia. Because of the preponder-
ance of genotypes B and C in Asian countries, the studies
are restricted to comparisons of patients with these two
genotypes. Nevertheless, such comparisons provide very
important information on the relation between HBV ge-
notype B and C and the rate of progression of liver disease,
since the age at the onset of infection is presumed to be the
same (perinatal period) in the vast majority of patients.
These studies clearly showed that compared to genotype
C, HBV genotype B is associated with spontaneous
HBeAg seroconversion at a younger age, less active liver
disease, and a slower rate of progression to cirrhosis.4–9
Some studies also found that genotype B patients are less
likely to have hepatitis flares and more likely to remain in
remission after HBeAg seroconversion.9 Most studies, in-
cluding those outside of Japan, reported that hepatocel-
lular carcinoma (HCC) development is less frequent and
occurs at an older age in patients with genotype B.7,8,10
These data indicate that a shorter duration of high levels
of HBV replication and less active necroinflammation
may contribute to a more favorable outcome among pa-
tients with genotype B. However, Kao et al. from Taiwan
found that genotype B (all subtype Ba) was more com-
mon in patients with HCC aged less than 50 years, sug-
gesting that genotype B may be associated with
accelerated progression to HCC.6 This finding is para-
doxical and needs to be confirmed.
There is a paucity of data on the clinical course of
patients with genotypes other than B and C. One study
from Spain reported that HBeAg seroconversion rates
were similar in patients with genotypes A and D, but
sustained biochemical and virological remission was more
common in patients with genotype A who had HBeAg
seroconversion.11 Patients with genotype A also had a
higher rate of HBsAg clearance. However, the need for
liver transplantation and the deaths related to liver disease
were comparable between patients with genotypes A and
D. In this study, patients with genotype F were more
likely to die from liver disease than those with genotypes A
or D, but only 19 patients with genotype F were included.
To date there has been no published study comparing
the rate of HBeAg seroconversion, activity of liver disease,
and rate of progression to cirrhosis and HCC among pa-
tients with all known HBV genotypes. The lack of such
studies is related to the preponderance of 1 or 2 HBV
genotypes in most geographical regions. The finding of
HBV genotypes A to G in the United States permits stud-
ies that compare the clinical course of HBV infection
among patients with a wider spectrum of HBV genotypes.
In one cross-sectional study of 694 patients in the United
States, genotypes B and D were associated with a lower prev-
alence of HBeAg than genotype A, while genotype B was
associated with a lower rate of hepatic decompensation com-
pared to genotype A, C, or D.3 However, other factors such
as differences in ethnic/racial background, age at onset and
duration of infection, and exposures to alcohol/environmen-
tal toxins rather than HBV genotypes may have contributed
to the differences in clinical manifestations.
HBV Genotypes and Treatment Response
HBV genotype has been reported to correlate with re-
sponse to interferon treatment in several studies. Two
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studies from Asia found that patients with HBV genotype
B had a higher rate of HBeAg seroconversion compared to
those with genotype C.12,13 One study from Germany
reported that patients with genotype A had a higher rate
of HBeAg seroconversion than those with genotype D.14
Although all 3 studies involved small numbers of patients,
these findings were confirmed by a recent study of pegy-
lated interferon (IFN), where HBeAg seroconversion oc-
curred more often in patients with genotypes A (47%)
and B (44%) than in those with genotypes C (28%) and
D (25%).15 Whether HBV genotypes play a role in IFN
response among patients with HBeAg-negative chronic
hepatitis has not been determined.
Unlike IFN, a correlation between HBV genotype and
response to lamivudine or adefovir dipivoxil therapy has
not been demonstrated. Several studies in Asia, all involv-
ing small numbers of patients and varying duration of
lamivudine treatment, showed that HBeAg seroconver-
sion and breakthrough infection occurred in similar pro-
portions of patients with genotypes B and C.16,17
However, two studies, one in HBeAg-positive and one in
HBeAg-negative patients found that patients with geno-
type B were more likely to sustain their response when
treatment was discontinued.18,19 A study of 78 German
patients reported that lamivudine-resistant mutants
emerged more rapidly in those with genotype A versus D,
but a correlation with response was not reported.20 Retro-
spective analysis of phase III clinical trials of adefovir dipiv-
oxil found that all HBV genotypes resulted in a similar
decrease in serum HBV DNA levels, but a correlation with
HBeAg seroconversion could not be determined because of
the small number of patients with HBeAg seroconversion.21
HBV Genotypes and Outcome of Acute HBV
Infection
There is very little information on the correlation be-
tween HBV genotypes and the outcome of acute HBV
infection. One study of 65 patients in Switzerland found
that 80% of patients with acute hepatitis B had genotype
D, while 80% patients with chronic hepatitis B had ge-
notype A.22 Another study found that 12% of 531 Japa-
nese patients with chronic HBV infection had genotype B
in contrast to 39% of 61 patients with acute hepatitis B.23
These data suggest that different HBV genotypes may be
associated with different rates of progression from acute to
chronic HBV infection. Alternatively, the data may indicate
a temporal change in predominant HBV genotype due to
immigration or a shift in mode of transmission.
In this issue of HEPATOLOGY, Garfein et al. reported an
outbreak of acute hepatitis B.24 Of the 21 patients iden-
tified, 20 were American Indians, and 20 admitted to
injecting illicit drugs. Eleven patients were hospitalized,
and 10 had fulminant hepatitis; all 10 with fulminant
hepatitis died. The high mortality rate led to further test-
ing to identify the viral strain and other risk factors that
contributed to the severity of the disease.
Full-length HBV genomic sequences were available on
7 patients with fulminant hepatitis and 1 control with
nonfulminant hepatitis. A partial sequence was available
on 1 additional control. All sequences were classified as
genotype D; analysis of hepatitis B cases in the U.S. Acute
Liver Failure Study also found a high prevalence of geno-
type D.25 Three sequences from the fulminant cases were
identical and represented the major sequence of the out-
break strain; sequences from the remaining 4 fulminant
cases differed by 1 to 9 nucleotides, while sequences from
the 2 controls differed by 2 to 9 nucleotides. These data
confirmed a common source outbreak and also demon-
strated that the HBV strain identified did not invariably
lead to a fulminant course. Sequences from additional
controls will help to strengthen this point.
The authors found many nucleotide and amino acid
changes between the major sequence in this outbreak and
other genotype D reference sequences. These differences
by no means prove that the HBV strain in this study is
more virulent. Indeed, precore stop codon and core pro-
moter mutations had previously been thought to be re-
sponsible for the fulminant course in several outbreaks
and case series,26–29 but these same mutations were also
found in the source patients who were frequently asymp-
tomatic carriers and in many patients with chronic HBV
infection. Furthermore, full-length HBV genomic se-
quencing in other case series of fulminant hepatitis B
failed to identify mutations that are consistently
present.30 The finding of more frequent and heavier ex-
posure to alcohol, acetaminophen, and injected metham-
phetamine or cocaine prior to hospitalization and
hepatitis C coinfection in all case patients suggests that
cofactors that cause liver injury may be more important
than viral factors in the fulminant course in the current
Fig. 1: Geographic distribution of hepatitis B virus genotypes.
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study. Similar observation was reported by the U.S. Acute
Liver Failure Study Group. Among the patients with hep-
atitis A or B, those who had measurable acetaminophen
levels had more pronounced aminotransferase elevations,
suggesting that acetaminophen enhances hepatocellular
injury in the setting of acute viral hepatitis.31
In summary, there is increasing evidence that HBV
genotype correlates with clinical outcomes of chronic
HBV infection and response to treatment. The evidence
for a clinical difference is stronger between genotypes B
and C, and in response to IFN but not nucleoside or
nucleotide treatment. The exact reason(s) why HBV ge-
notype may be related to clinical outcomes is not clear. It
is possible that different genotypes may be associated with
differences in replication fitness and expression of im-
mune epitopes. There is also a clear association between
HBV genotypes and precore and core promoter muta-
tions. While the story of HBV genotypes continues to
unfold at a rapid pace, genotyping should remain a re-
search tool until the time when knowledge of the HBV
genotype can be used to predict the risk of adverse out-
comes (fulminant hepatitis, cirrhosis, or HCC) or to
guide treatment decisions (choice or duration of therapy).
SCOTT K. FUNG
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